Long nonprotein-coding RNAs (lncRNAs) are generally defined as a category of nonprotein-coding transcripts more than 200 nucleotides in length. lncRNA genes cover approximately 90% of the human genome [14] . In recent years, it has become evident that lncRNAs are involved in a variety of cell processes [13,5] , particularly during development and diseases [1,2,6]. Like microRNAs (miRNAs), a well-studied class of small nonprotein-coding RNAs, lncRNAs have also been shown to be highly involved in hematopoietic development, including proliferation, differentiation, and apoptosis of hematopoietic stem cells, as well as progenitors and precursors of multi-lineage mature blood cells, which include erythrocytes, megakaryocytes, myelocytes (monocyte, macrophage and neutrophil), and lymphocytes (B-cell and T-cell) [715] . Several findings suggest that dysregulation of the lncRNAs can lead to abnormal modulation of multiple cellular pathways, and result in various hematological malignancies, including lymphoma, multiple myeloma and leukemia, which together account for nearly 7% of all cancer diagnoses [12,1619] . Dysregulation of the lncRNAs can also lead to anemia, which is the most common disorder of the blood system [14] . These involvements suggest the potential clinical relevance of lncRNAs in the diagnosis, prognosis, and therapy of these blood diseases.
lncRNAs regulate gene transcription and translation through different mechanisms, including interaction with RNA-binding proteins to reduce the translation activity of mRNA, recruiting protein complex to epigenetically regulate gene expression, and competition with mRNAs for shared miRNAs to act as post-transcriptional modifiers [13,20] . Although the mechanisms underlying the function of most lncRNAs are not fully understood, functional annotation has provided a complex regulation theory and classification for lncRNAs [21] . Importantly, accumulating evidence suggests that lncRNAs have multiple functions in normal and malignant hematopoiesis [1114, 16, 17] , and these clues help better understand the biology of hematopoiesis and blood diseases. In this review, we summarize the recent progress in our understanding of some of the mechanisms behind the involvement of lncRNAs in blood development and blood diseases through their function in modulating crucial susceptibility genes in diverse pathways. We also discuss the use of genome-wide lncRNA studies for screening potential biomarkers or therapeutic targets in blood disease treatment.
lncRNAs involved in normal hematopoiesis
Unlike mRNAs and miRNAs, lncRNAs are poorly conserved among species; however, a proportion of human lncRNAs share similar functions with murine orthologs, such as Xist, H19 and Tmevpg1 [4] . Therefore, several studies that focus on these lncRNAs in mouse model also provide important information for a better understanding of hematopoiesis. lncRNA expression levels in normal hematopoiesis have been studied in both murine and human blood cells, and a number of lineage-specific expressed lncRNAs are considered as spatiotemporal regulators of blood development [11, 14] (Figure 1 , left).
Erythroid development-related lncRNAs
Erythroid development, which is the process that produces red blood cells, is essential for the circulation system. A murine lncRNA, lincRNA-EPS, is a long intergenic non-coding RNA that was found to be highly specific to terminally differentiating erythroid cells [14] . The expression of lincRNA-EPS was strongly induced when erythroid precursors begin to synthesize hemoglobin and other lineage-specific proteins, while the inhibition of lincRNA-EPS was shown to block differentiation and promote apoptosis of erythroid progenitors, which might be related to the proapoptotic gene Pycard [14] . Briefly, lincRNA-EPS might bind to the Pycard locus and recruit transcriptionally repressed complexes to suppress the expression of Pycard. Reduced Pycard expression may not be enough to promote cell death by activating intercellular caspases, and thus normal erythroid differentiation is induced. Although the protein components associated with lincRNA-EPS in regulating erythroid differentiation are unclear, lincRNA-EPS is the first lncRNA to be related to red blood cells; however, whether this lncRNA is evolutionarily conserved in human is still unknown. Because anemia is generally caused by a lack of red blood cells or hemoglobin, lncRNAs that are involved in erythropoiesis could potentially be exploited for the treatment of anemia and other blood diseases.
Myeloid differentiation-related lncRNAs
Myelocytes are important in the innate immune system, and abnormal proliferation and differentiation of myeloid cells are associated with acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). Eosinophil granule ontogeny (EGO) is a myeloid progenitor differentiation-related lncRNA, which is transcribed antisense to an intron of inositol triphosphate receptor type 1 (ITPR1). EGO is highly expressed in human bone marrow and in mature eosinophils [11] . Following interleukin-5 (IL-5) stimulation, EGO transcript levels increased rapidly in both CD34 + hematopoietic progenitors purified from mononuclear cord blood and bone marrow mononuclear cells, and then returned to basal level within 72 h. It was proposed that EGO can affect myeloid development by regulating the expression of eosinophil genes, including major basic protein (MBP) and eosinophil derived neurotoxin (EDN), in developing CD34 + hematopoietic progenitors [11] . Because EGO maintains a high expression level in the CD34 + erythroleukemic cell line TF-1, and a variety of blood diseases are caused by abnormalities of hematopoietic progenitor differentiation, especially myeloid progenitor differentiation, dysregulated or mutant EGO transcripts might serve as a potential etiology of blood diseases, such as erythroleukemia, myeloproliferative disorder, and myeloid leukemia [11] .
Another lncRNA, HOTAIRM1, has been identified as an essential regulator of retinoic acid-induced myeloid cell differentiation [12] . It was found that the expression levels of HOTAIRM1 showed a positive correlation with its neighboring gene, HOXA1, and knock-down of HOTA-IRM1 prevented the expression of HOXA1, HOXA4, CD11b, and CD18, which are essential transcription factors and antigens in myeloid cell differentiation. Moreover, the murine Hotairm1 was found to interact with the chromatin remodeling complexes, polycomb repressor complex 1 (PRC1) and PRC2 [22] , which implies that HOTAIRM1 might maintain myeloid differentiation epigenetically in both human and murine. Because retinoic acid is an important drug in myeloid leukemia treatment [23] , HOTAIRM1 might serve as a pivotal therapy target for some leukemia subtypes.
Lymphoid differentiation and immune-related lncRNAs
A number of lncRNAs are involved in the development and function of T-cells and B-cells, and because of the essential role of these lymphocytes in the adaptive immune system, these lncRNAs are generally involved in immune reactions.
Non-coding RNA repressor of NFAT (NRON) is present in a cytoplasmic RNA-protein scaffold complex that in- TMEVPG1 and Thy-ncR1), and these lncRNAs contribute to maintaining normal hematopoiesis. Dysregulated lncRNAs may disorder the biology of hematopoietic cells. For example, dysregulated HOTAIR, HOTAIRM1, Mira, or Linc-HOXA1 leads to the deregulation of HOX genes, mis-expressed ANRIL leads to disordered cell cycles, abnormal expression of MEG3, PVT1, DLEU1 or DLEU2 results in activation of oncogenes and inhibition of tumor suppressors, and dysregulated H19 and XIST leads to abnormal imprinting and X-aneuploidies, respectively. These disorders triggered by dysregulated lncRNAs result in blood diseases.
cludes phosphorylated NFAT1, a Ca 2+ -regulated transcription factor that controls gene expression in T-cell differentiation. Knock-down of NRON increases NFAT dephosphorylation, nuclear import (exclusively after stimulation), and production of NFAT-dependent cytokines [24] . Moreover, because lymphocytes are essential for the adaptive immune system, lncRNAs that are associated with lymphoid differentiation must also have an immune-related function. Another T-cell differentiation-related lncRNA, Thy-ncR1, is expressed specifically in cell lines derived from stage III immature T-cells, and might participate in T-cell selection and maturation by controlling the degradation of MFAP4 mRNA [13] . In addition, in the stage III immature T-cells, the CD1 gene cluster, which neighbors Thy-ncR1, is also activated specifically. Although it is unclear whether the expression of Thy-ncR1 is linked mechanistically to the activation of the CD1 gene cluster, the co-expressed phenomenon of the CD1 gene cluster and Thy-ncR1 implies a potential synergistic effect of CD antigens and lncRNAs during T-cell selection and maturation [13] . Besides, TMEVPG1, a lncRNA studied in both murine and human, is located adjacent to the interferon-g (IFNG) gene, and induces IFN-g synthesis in a series of T-cells [25, 26] . Considering the importance of IFN-g in T-cell selection, maturation and immunization, TMEVPG1 plays multiple roles in lymphopoiesis, including driving the Th1 cell differentiation program [25] and increasing Theiler's virus persistence of activated CD8 + T-cells [26] . Further studies have revealed that TMEVPG1 activates IFNG by binding to WDR5, a component of the histone H3 lysine 4 (H3K4) methyltransferase complex, and altering the histone methylation level at the IFNG locus [26] . These findings suggest that lncRNAs might control T-cell differentiation and susceptibility of pathogens by regulating the abundance of pivotal cytokines at the transcriptional level.
Compared with lncRNAs in T-cells, only a few lncRNAs have been reported in B-cell differentiation. One such lncRNA is B-cell integration cluster (BIC), a lncRNA that is highly expressed in both activated B-cells and T-cells and in monocytes/macrophages; however, no evidence of BIC acting as a "long" RNA has been found yet [27] . So far, most of the studies on BIC have been focused on its processed products, miR-155-5p and miR-155-3p, which play critical roles in various physiological and pathological processes, such as hematopoietic lineage differentiation, immunity, inflammation, and viral infections [28] . Because many functional lncRNAs also contain miRNAs in their exons (e.g., H19 [29] and PVT-1 [30] ), BIC might be involved in hematopoiesis not merely by acting as a host gene of miR-155.
In conclusion, lncRNAs play critical roles in normal hematopoiesis by regulating pivotal hematopoietic factors or cytokines, which maintain the biology balance and normal operation of the hematopoietic and immune systems, as summarized in Figure 1 . Dysregulation of these lncRNAs might lead to abnormal hematopoiesis, which results in a variety of blood diseases, for example, polycythemia, thrombosis, and stroke, by reason of erythropoiesis disorder; anemia, including thalassemias and aplastic anemia; and malignant hematopoiesis, including multiple myeloma, myelodysplasia, and various subtypes of leukemia.
lncRNAs associated with blood diseases interact with crucial susceptibility genes in different pathways
Many lncRNAs show cancer-specific expression [2] , and the biologic features of these lncRNAs suggest that they might be involved in the pathogenesis of human diseases. Typically, lncRNAs execute molecular functions through four major known mechanisms: by acting as signals, decoys, guides, or scaffolds [31] . But in all cases, lncRNAs participate in diseases by mis-regulating target genes or pathways, which are essential factors of disease occurrence.
lncRNAs regulate these genes and pathways either in cis or in trans [1, 31] . Although it is still controversial whether mammalian lncRNAs generally act in cis or in trans, both categories of lncRNAs imply a direct influence on target genes [1]. The cis-acting lncRNAs are restricted to the site of synthesis, and directly influence one or several genes on the same chromosome. They are located near diseaserelated genes, which might indicate that they have the potential to serve as disease repressors or therapy targets. By contrast, trans-acting lncRNAs diffuse across the whole genome and can influence target genes on other chromosomes, which might regulate a series of genes in a certain pathway. Studies on trans-acting lncRNAs have also provided an understanding of the possible etiology of human diseases. Emerging evidence suggests a number of lncRNAs regulate pivotal blood disease-related factors including transcriptional factors [12, 32] , CD antigens [12] , and cyclin-dependent kinases [33, 34] , as well as essential hematopoietic pathways, both in cis and in trans (Figure 1, right) . These findings have greatly expanded our knowledge of blood development and diseases.
lncRNAs interact with HOX gene clusters in malignant hematopoiesis
There are a set of genes that are specifically expressed in hematopoietic stem cells, progenitors, and mature blood cells. One cluster of these genes is the highly conserved HOX transcription factor genes [35] . These HOX genes also have specific patterns of lineage-restricted expression, whereby HOXA genes are expressed in myeloid cells, HOXB genes in erythroid cells, and HOXC genes in lymphoid cells [35] . Many lncRNAs are located in HOX loci in both human and murine, and miRNAs are found to be frequently located inside or near HOX loci with a 15.77 times higher incidence rate, as reported in a previous study [36] . Although there is no similar report on lncRNAs, numerous lncRNAs have been identified in HOX loci, which account for a large proportion of the known lncRNAs [37] . Moreover, some of these HOX-lncRNAs have been found to play potent roles by controlling the expression of HOX genes at the transcriptional level [12,3840] .
One such example is HOTAIR, a lincRNA located intergenic and antisense to the flanking HOXC11 and HOXC12 genes [41] . Dysregulation of HOTAIR has been shown to be involved in a variety of cancers, including breast carcinoma [42] , hepatocellular carcinoma [43, 44] , colorectal cancer [45] , and lung cancer [46] . HOTAIR binds to EZH2, a component of the H3K27 methylation complex PRC2, which leads to the genome-wide re-targeting of the PRC2 complex, and a 40-kb region of the HOXD locus is transcriptionally silenced by HOTAIR [47] . Another example is HOTAIRM1, the myeloid differentiation-related lncRNA mentioned above, which is also found to bind with the PRC2 complex [22] , and which could regulate the expression of its neighboring HOXA1 gene [12] . Although it is still unclear whether the regulation of HOXA1 is performed by targeting the PRC2 complex to HOXA1 locus, it is certain that HOTAIRM1 plays a pivotal role in controlling HOXA gene expression. A third murine lncRNA Mira, is transcribed from a region between Hoxa6 and Hoxa7, and the Mira transcript is required for the recruitment of H3K4 histone methyltransferase Mll1 to the Mira gene locus and the activation of Hoxa6 and Hoxa7 [40] . Interestingly, not all HOX-lncRNAs regulate HOX genes by regulating histone methylation. Linc-HOXA1 is a murine lncRNA adjacent to Hoxa1, which represses Hoxa1 transcription in cis by interacting with PURB, which is an important transcriptional factor during hematopoiesis in murine embryonic stem cells [38] .
It is worth noting that HOTAIR restrains the expression of HOX genes in trans and Mira activates the HOXA genes in cis [40, 47] , which suggests that these lncRNAs located in HOX clusters could control HOX gene expression by different modifications, and that linc-HOXA1 regulates HOXA1 expression in a different way [38] . All these researches indicate that HOX-lncRNAs regulate HOX genes in a variety of different ways in complicated regulatory networks, though most parts of these networks are still unknown. Among the HOX-lncRNAs, only HOTAIRM1 has been proved to participate in hematopoiesis [12] . However, the HOX-lncRNAs that take part in the regulation of HOX genes and exhibit expression correlations with their neighboring HOX genes also showed a high probability of being involved in blood development [37] . There are still many HOX-lncRNAs with unknown functions. Therefore, further studies focused on HOX-lncRNAs will help in understanding the complex regulation networks of HOX-lncRNAs and HOX genes, as well as functional miRNAs in the HOX locus, and might provide deeper insights into the mechanisms of normal and malignant hematopoiesis. Indeed, it is likely that these HOX-related lncRNAs represent useful therapeutic agents and targets for multiple blood diseases.
ncRNAs control cell cycle in leukemia
Cell cycle disorder is one of the most important causes of leukemia incidence, and numerous cyclins and cyclindependent kinases are regarded as vital oncogenes or tumor suppressors [4850] . A cell cycle-related lncRNA, ANRIL, is located antisense of the INK4b-ARF-INK4a locus, which encode three critical cyclin-dependent kinase inhibitors, p15 INK4b , p14 ARF and p16 INK4a [16] . The p15
INK4b
, p14 ARF and p16
INK4a inhibitors are epigenetically silenced in hematopoietic stem cells and play central roles in cell cycle inhibition, senescence, differentiation, and stress-induced apoptosis, especially in various hematological malignancies [51] , and the occurrence of p16 INK4A /p14 ARF /p15 INK4b alters the prognosis or disease progression in a variety of leukemia subtypes [51, 52] . For example, deletion of p15
INK4b and p16 INK4a was reported in acute lymphoblastic leukemia (ALL) (>30%) [51] and BCR-ABL-induced leukemia [53] . Intriguingly, Iacobucci et al. [54] found a polymorphism in ANRIL locus that is associated with BCR-ABL-induced ALL, which might be a thread for deregulation of INK4 locus in some subtypes of leukemia. Furthermore, Yu et al. [16] discovered an inverse relation between ANRIL and p15 expression in leukemia, implying an ANRIL-dependent regulation mechanism for p15 in leukemia. This hypothesis was supported in subsequent studies. ANRIL was found to bind to SUZ12 and CBX7, which are components of PRC1 and PRC2, respectively, and recruiting these complexes to the INK4 locus, which led to the subsequent silencing of this gene locus by H3K27-trimethylation [34] . This cis-regulation of the INK4 locus by ANRIL might help explain leukemia pathogenesis, whereby, the over-expression of ANRIL epigenetically silenced p14, p15, and p16, which are repressors of leukemia, and induced cell cycle disorder, differentiation block, and apoptosis arrest in blood cells, which lead to the occurrence of leukemia. Further validation of this mechanism in hematopoietic cells might provide an effective target for the treatment of some leukemia subtypes.
ANRIL is the only cell-cycle related lncRNA that has been found to be involved in leukemia. However, other lncRNAs are known to control the cell cycle in normal somatic cells, for example, MALAT1 in diploid fibroblasts [55] , and lncRNA-LALR1 in hepatocytes [56] , and in other cancer cells, for example, UCA1 in bladder carcinoma [57] , and MEG3 in cervical carcinoma [58] . Further screening and research on cell-cycle related lncRNAs will also assist in targeting therapy in a series of blood diseases, especially in leukemias with cell cycle disorder.
lncRNAs regulate oncogenes and suppressor genes in malignant hematopoiesis
Malignant hematopoiesis is generally considered to be caused by dysregulated expression of oncogenes and tumor suppressors. Although the underlying mechanism of these abnormal expressions is unclear, lncRNAs might be an appropriate explanation of the problem. P53, which maintains genomic integrity and triggers cellular senescence, cell cycle control and apoptosis of damaged cells, is dysregulated or mutated in over half of human cancers and about 13% of hematological malignancies [59, 60] . MEG3, a myelocyterelated lncRNA, is highlighted in multiple human malignancies [61] and MEG3 is a lncRNA that regulates p53, which might partially explain the aberrations of the p53 tumor suppressor pathway in some subtypes of malignant hematopoiesis. As an important regulator for proper growth and development and a putative tumor suppressor, MEG3 activates p53, inhibits cell proliferation, and might control its downstream genes by recruiting the PRC2 complex and epigenetically repressing gene expression levels [62] . MEG3 was found to display aberrant hypermethylation in its promoter region in nearly half of a cohort of 85 MDS and AML patients [19] . Another independent assessment of 40 AML samples also confirmed the aberrant methylations [18] . The hypermethylation of the MEG3 promoter also correlates with decreased overall survival, which can serve as a prognosis marker in myeloid malignancies [19] . Because AML is a heterogeneous group of genetically and phenotypically aggressive disorders in which the differentiation of hematopoietic progenitor cells is blocked, it is highly probable that MEG3 plays an important role in myeloid differentiation. It is reasonable to assume that the interactions of MEG3 with MDM2, p53, GDF15, and p16 in other cancers will likely demonstrate a role for MEG3 that is similar to its role in leukemia [63] . These proposals need further experimental validations.
The proto-oncogene MYC is another important gene involved in malignant hematopoiesis. MYC plays a pivotal role in cell cycle regulation, metabolism, apoptosis, differentiation, cell adhesion, and tumorigenesis, and participates in regulating hematopoietic homeostasis [64] . lncRNA PVT-1 is adjacent to the MYC gene locus and is frequently involved in the translocations that occur in about 20% of Burkitt's lymphoma and 16% of multiple myeloma, as well as in most murine plasmacytomas [30, 65, 66] . Apart from forming fusion genes, PVT-1 is suggested to be a MYC activator, and has also been proved to be regulated by MYC, which implies a feedback regulation mechanism [66] . Although details of the interaction between PVT-1 and MYC remain unrevealed, further investigation of this mechanism might provide a powerful therapy approach for malignant hematopoiesis.
In addition to the single genes, some relevant pathways are also involved in hematological malignancies. One example is the NF-B signaling pathway, which is centrally involved in the homeostasis of the hematopoietic system where it is induced in inflammation and inhibits apoptosis, and is activated in chronic lymphocytic leukemia (CLL) [67] . A recent study reported that two lncRNAs, DLEU1 and DLEU2, map to a critical region that is recurrently deleted in CLL [67] . In CLL patients, substantial DNAdemethylation and enriched histone H3K4 methylation at the transcriptional start sites of DLEU1 and DLEU2 were found. These two lncRNAs might control a series of genes in the NF-B pathway, either by inducing or repressing the pathway activity, implying that DLEU1 and DLEU2 exert a precise and complicated NF-B pathway regulating mechanism [67] . In brief, some lncRNAs regulate pivotal oncogenes, tumor suppressors or relevant pathways in malignant hematopoiesis, which suggests an important focus of further study, even though, at present, little is known about these mechanisms.
lncRNAs interact with imprinted genes in hematological malignancies
Abnormal imprinting is also an important pathogenesis in many blood diseases [68, 69] . One of the earliest described lncRNAs, H19, is involved in imprinting regulation of its neighboring gene IGF2, as well as in trans-regulation of a group of imprinted genes, including Igf2r and Dlk1 [70, 71] , suggesting an important role for H19 in genomic imprinting during growth and development. H19 is considered to be an oncogene or tumor suppressor in different cancers [7174] . In malignant hematopoiesis, expression of H19 is reduced in AML and CML [75, 76] , as well as in chronic MDS [75] . Loss of imprinting at the H19 locus that results in high H19 expression was found in adult T-cell leukemia and lymphoma patients [77] , suggesting that H19 plays disparate roles in different leukemia subtypes. Accumulating evidence suggests that H19 could bind PRC2 [62] and Igf2 mRNA binding-protein 1 (IMP1) [78] , which could regulate gene expression levels by both chromatin remodeling and post-transcriptional processes. Moreover, H19 also contains the precursor of miR-675 in exon one [29] , suggesting that H19 might serve as a bi-functional RNA which can act either as a miRNA or an lncRNA in different regulation pathways and cell contexts. This makes the regulation mechanism of H19 more complicated, and might help to explain the conflicting reports that it acts as both a tumor suppressor and oncogene in malignant hematopoiesis. Because of its widespread and complicated roles in blood disease, further research to identify how H19 functions as a full-length lncRNA or miR-675 in different cell contexts might reveal the underlying mechanisms of H19 regulation. Further identification of target genes of both lncRNA H19 and miR-675 in malignant hematopoiesis could also provide potential specific therapeutic targets for different subtypes of leukemia. In addition, H19 is regarded as a prognosis marker in multiple cancers [73, 74, 79, 80] , and the prognostic implication of H19 in blood disease is also worth exploring to develop lncRNA-based diagnosis and lncRNAmediated therapy.
lncRNAs associated with X-chromosome inactivation in hematological malignancies
A large number of lncRNAs are located in the X chromosome and participate in X chromosome inactivation, including XIST, TSIX, JPX, and XITE [1]. These X chromosome-inactive related lncRNAs silence gene expression by the epigenetic modification of histones and DNA in a complicated interaction model. X chromosome aneuploidies, on the other hand, have long been associated with human cancers, but the causality was not established until recently [17] . Yildirim et al. [17] deleted Xist in the blood of mice and demonstrated that mutant females develop a highly aggressive myeloproliferative neoplasm and MDS with 100% penetrance, which suggested that Xist loss results in X reactivation and induces significantly higher abundance of X-linked genes, including some oncogenes. Thus, it was confirmed that Xist is required not only to maintain X chromosome inactivation, but is also necessary in suppressing cancer in vivo. Although no studies on other X chromosome-inactive-related lncRNAs in blood diseases have been performed, because abnormal X chromosome inactivation might cause various blood diseases, it is possible that these X chromosome-inactive-related lncRNAs might also be involved in blood disease suppressing.
To summarize, a great many nonprotein-coding transcripts that are relevant in normal and malignant hematopoiesis have been found to regulate their target genes by RNA interference or silencing at the chromatin level, as depicted in Figure 1 . However, our knowledge of these lncRNAs is just the tip of the iceberg; thus, further research and information mining about these lncRNAs are still required.
Genome identification of lncRNAs might provide new targets for blood diseases
High-throughput sequencing and microarray analysis have provided powerful tools to obtain global cell transcriptome profiles, which can be used to screen potential lncRNAs with physiological functions in the biology of blood diseases [81, 82] . These genomic studies will also provide databases for further functional studies. A transcriptome sequencing study of the Sezary syndrome, one of the most common forms of cutaneous T-cell lymphoma, was performed recently by Lee et al. [83] . Thirteen unannotated lncRNAs were found to be differentially expressed in Sezary syndrome. The functional annotation of these Sezary syndrome-associated lncRNAs will provide further insights into the mechanisms of Sezary syndrome pathogeny. Although only a small number of genome-wide studies of this type have been performed till now, such studies may detect potent lncRNAs involved in leukemia classification and therapy.
Another class of genome-wide studies on lncRNAs is the screening of DNA and histone modifications, and transcription factor binding sites by chromatin immunoprecipitation followed by sequencing (ChIP-seq), which has provided the modification profiles of lncRNAs [81, 84] . These data have contributed to in-depth knowledge of the spatiotemporal expression pattern of lncRNAs, which has provided further clues and evidence for understanding the function of blood disease-specific lncRNAs. Although some ChIP-seq data for blood cell lines have been provided by the ENCODE project [85] , ChIP-seq of patients with blood diseases and of cells under different treatments are still important for lncRNA screening. In addition, the re-analysis of previous ChIP-seq data that were focused on mRNAs may also help in identifying lncRNAs associated with various blood diseases.
A third class of genome-wide studies is RNA immunoprecipitation followed by sequencing (RIP-seq) [62] . Many lncRNAs bind to protein complexes, therefore, the RIP-seq studies on different cells could indicate potential functions of lncRNAs that bind with known complexes. A combined analysis of RNA expression data and ChIP-seq data might help define the function of some lncRNAs. Genome-wide data provides the opportunity for researchers to select pivotal lncRNAs in blood disease, and to predict the potent functional mechanism of these lncRNAs. Thus far, only a few genome-wide lncRNA studies on blood disease have been performed and future genome-wide research on lncRNAs would help to explain the mechanisms of lncRNAs, which may contribute to the diagnosis and treatment of blood diseases.
Conclusion and perspectives
Emerging studies have defined lncRNAs as an important aspect of development, and accumulating evidence suggests that lncRNAs play central roles in hematopoiesis; however, the mechanisms of action of the majority of lncRNAs in normal and malignant hematopoiesis are still unclear. Future genome-wide screening and in-depth functional studies on the lncRNAs are urgently needed to provide insights into the interaction networks of lncRNAs, mRNAs, and miRNAs in the biology of normal and malignant hematopoiesis. Such studies might offer powerful clinical tools and novel molecular strategies for blood disease diagnosis, prognosis and therapy. 
